ID: ALA5179012

Max Phase: Preclinical

Molecular Formula: C48H69N7O11

Molecular Weight: 920.12

Associated Items:

Representations

Canonical SMILES:  COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@H](CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)OC(=O)OC(OC(=O)[C@H](N)C(C)C)C(C)C)C(C)(C)C

Standard InChI:  InChI=1S/C48H69N7O11/c1-29(2)37(49)42(58)65-43(30(3)4)66-46(61)64-36(35(26-31-18-14-13-15-19-31)51-40(56)38(47(5,6)7)52-44(59)62-11)28-55(54-41(57)39(48(8,9)10)53-45(60)63-12)27-32-21-23-33(24-22-32)34-20-16-17-25-50-34/h13-25,29-30,35-39,43H,26-28,49H2,1-12H3,(H,51,56)(H,52,59)(H,53,60)(H,54,57)/t35-,36-,37+,38+,39+,43?/m0/s1

Standard InChI Key:  DLUXWMAGQWCCLR-VBIXTJAZSA-N

Associated Targets(Human)

UGT1A1 Tchem UDP-glucuronosyltransferase 1-1 (448 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 920.12Molecular Weight (Monoisotopic): 919.5055AlogP: 5.88#Rotatable Bonds: 20
Polar Surface Area: 238.84Molecular Species: NEUTRALHBA: 14HBD: 5
#RO5 Violations: 3HBA (Lipinski): 18HBD (Lipinski): 6#RO5 Violations (Lipinski): 4
CX Acidic pKa: 11.77CX Basic pKa: 7.48CX LogP: 7.34CX LogD: 7.00
Aromatic Rings: 3Heavy Atoms: 66QED Weighted: 0.04Np Likeness Score: -0.08

References

1. A M Subbaiah M, Subramani L, Ramar T, Desai S, Sinha S, Mandlekar S, Kadow JF, Jenkins S, Krystal M, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Meanwell NA..  (2022)  Improving Drug Delivery While Tailoring Prodrug Activation to Modulate Cmax and Cmin by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir.,  65  (16.0): [PMID:35952307] [10.1021/acs.jmedchem.2c00632]
2. A M Subbaiah M, Subramani L, Ramar T, Desai S, Sinha S, Mandlekar S, Kadow JF, Jenkins S, Krystal M, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Meanwell NA..  (2022)  Improving Drug Delivery While Tailoring Prodrug Activation to Modulate Cmax and Cmin by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir.,  65  (16.0): [PMID:35952307] [10.1021/acs.jmedchem.2c00632]

Source